1. Contraceptives and teens: what are the options? Contracept Technol Update. Sep 2000;21(9):109-111.
Link to PubMed
2. Busen NH. Bone mineral density in adolescent women using depot medroxyprogesterone acetate. J Am Acad Nurse Pract. Feb 2004;16(2):57-62.
Link to PubMed
3. Busen NH, Britt RB, Rianon N. Bone mineral density in a cohort of adolescent women using depot medroxyprogesterone acetate for one to two years. J Adolesc Health. Apr 2003;32(4):257-259.
Link to PubMed
4. Chotnopparatpattara P, Taneepanichskul S. Use of depot medroxyprogesterone acetate in Thai adolescents. Contraception. Sep 2000;62(3):137-140.
Link to PubMed
5. Cromer BA. Bone mineral density in adolescent and young adult women on injectable or oral contraception. Curr Opin Obstet Gynecol. Oct 2003;15(5):353-357.
Link to PubMed
6. Cromer BA, Berg-Kelly KS, Van Groningen JP, Seimer BS, Ruusuvaara L. Depot medroxyprogesterone acetate (Depo-Provera) and levonorgestrel (Norplant) use in adolescents among clinicians in Northern Europe and the United States. J Adolesc Health. Aug 1998;23(2):74-80.
Link to PubMed
7. Cromer BA, Blair JM, Mahan JD, Zibners L, Naumovski Z. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr. Nov 1996;129(5):671-676.
Link to PubMed
8. Cromer BA, Lazebnik R, Rome E, et al. Double-blinded randomized controlled trial of estrogen supplementation in adolescent girls who receive depot medroxyprogesterone acetate for contraception. Am J Obstet Gynecol. Jan 2005;192(1):42-47.
Link to PubMed
9. Cromer BA, Stager M, Bonny A, et al. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J Adolesc Health. Dec 2004;35(6):434-441.
Link to PubMed
10. Davis AJ. Use of depot medroxyprogesterone acetate contraception in adolescents. J Reprod Med. May 1996;41(5 Suppl):407-413.
Link to PubMed
11. Gordon CM, Nelson LM. Amenorrhea and bone health in adolescents and young women. Curr Opin Obstet Gynecol. Oct 2003;15(5):377-384.
Link to PubMed
12. Haefner HK, Elkins TE. Contraceptive management for female adolescents with mental retardation and handicapping disabilities. Curr Opin Obstet Gynecol. Dec 1991;3(6):820-824.
Link to PubMed
13. Khoiny FE. Use of depo-provera in teens. J Pediatr Health Care. Sep-Oct 1996;10(5):195-201.
Link to PubMed
14. Lara-Torre E, Edwards CP, Perlman S, Hertweck SP. Bone mineral density in adolescent females using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol. Feb 2004;17(1):17-21.
Link to PubMed
15. Lloyd T, Lin HM, Eggli DF, Dodson WC, Demers LM, Legro RS. Adolescent Caucasian mothers have reduced adult hip bone density. Fertil Steril. Jan 2002;77(1):136-140.
Link to PubMed
16. Mangan SA, Larsen PG, Hudson S. Overweight teens at increased risk for weight gain while using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol. Apr 2002;15(2):79-82.
Link to PubMed
17. Matson SC, Henderson KA, McGrath GJ. Physical findings and symptoms of depot medroxyprogesterone acetate use in adolescent females. J Pediatr Adolesc Gynecol. Feb 1997;10(1):18-23.
Link to PubMed
18. Middleman AB, Robertson LM, DuRant RH, Chiou V, Emans SJ. Use of hormonal methods of birth control among sexually active adolescent girls. J Pediatr Adolesc Gynecol. Nov 1997;10(4):193-198.
Link to PubMed
19. O'Dell CM, Forke CM, Polaneczky MM, Sondheimer SJ, Slap GB. Depot medroxyprogesterone acetate or oral contraception in postpartum adolescents. Obstet Gynecol. Apr 1998;91(4):609-614.
Link to PubMed
20. Paiva LC, Pinto-Neto AM, Faundes A. Bone density among long-term users of medroxyprogesterone acetate as a contraceptive. Contraception. Dec 1998;58(6):351-355.
Link to PubMed
21. Pelkman CL, Chow M, Heinbach RA, Rolls BJ. Short-term effects of a progestational contraceptive drug on food intake, resting energy expenditure, and body weight in young women. Am J Clin Nutr. Jan 2001;73(1):19-26.
Link to PDF
22. Pinkston Koenigs LM, Miller NH. The contraceptive use of Depo-Provera in U.S. adolescents. J Adolesc Health. May 1995;16(5):347-349.
Link to PubMed
23. Polaneczky M, Liblanc M. Long-term depot medroxyprogesterone acetate (Depo-Provera) use in inner-city adolescents. J Adolesc Health. Aug 1998;23(2):81-88.
Link to PubMed
24. Rome E, Ziegler J, Secic M, et al. Bone biochemical markers in adolescent girls using either depot medroxyprogesterone acetate or an oral contraceptive. J Pediatr Adolesc Gynecol. Dec 2004;17(6):373-377.
Link to PubMed
25. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med. Feb 2005;159(2):139-144.
Link to PubMed
26. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. The association between depot medroxyprogesterone acetate contraception and bone mineral density in adolescent women. Contraception. Feb 2004;69(2):99-104.
Link to PubMed
27. Sorensen MB, Collins P, Ong PJ, et al. Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance. Circulation. Sep 24 2002;106(13):1646-1651.
Link to PDF
28. Sowers MF, Scholl T, Harris L, Jannausch M. Bone loss in adolescent and adult pregnant women. Obstet Gynecol. Aug 2000;96(2):189-193.
Link to PubMed
29. Templeman CL, Cook V, Goldsmith LJ, Powell J, Hertweck SP. Postpartum contraceptive use among adolescent mothers. Obstet Gynecol. May 2000;95(5):770-776.
Link to PubMed
